Press Room

39th Symposium on Particulate Preparations and Designs

Start
Tuesday, November 29, 2022 - 09:00
End
Wednesday, November 30, 2022 - 18:00
Location: Himeji, Japan

 

Schedule your meeting today with Yasushi Usuda - Regional Sales Director
yasushi-usuda-photo
 

 

 

Let’s discuss your project together.

 

Yasushi Usuda will be a speaker at the symposium.

 

  • Title: Dispersome Technology – A new tool for solubility enhancement 
  • Abstract: The Dispersome® technology is based on the use of whey protein isolate to create so called Dispersomes® – a unique amorphous composition of small molecule drugs and proteins shown to be superior in terms of amorphous stabilization, dissolution and solubility enhancement as well as improvements in bioavailability, achieving drug loadings of 50 wt% and higher. The technology is offered together with ASD-HIPROS, Hovione’s Intelligent Proprietary Screening, is the most advanced and accurate tool to identify Amorphous Solid Dispersion (ASD) formulations by Spray Drying with maximum performance and stability. To further enhance the chances of identifying the best performing ASD formulation we have included Dispersome® into ASD-HIPROS to expand formulation options beyond polymeric excipients.

 

Schedule a meeting today!

 

 

Also in the Press Room

See All

The global inhalation contract development and manufacturing organization (CDMO) market is projected to grow from USD 9.13 billion in 2025 to USD 16.68 billion by 2035, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period. This growth is driven by the increasing prevalence of respiratory diseases, advancements in inhalation drug delivery technologies, and the rising demand for outsourced manufacturing services in the pharmaceutical industry. The inhalation CDMO market has emerged as a pivotal segment in the pharmaceutical contract development and manufacturing industry. With a rising demand for inhaled therapies for conditions like asthma, COPD, and cystic fibrosis, companies are increasingly outsourcing drug development and production to specialized partners. Inhalation CDMO services cater to both large pharmaceutical corporations and small biotech firms, offering expertise in formulation, device compatibility, regulatory support, and scale-up manufacturing. This market is gaining traction due to the complexity of inhalation drug delivery, which often requires niche technical capabilities and specialized equipment. Outsourcing to an inhalation CDMO allows drug developers to reduce time-to-market while ensuring quality and compliance with global standards. (...) Top Companies Several players dominate the inhalation CDMO market through technological expertise, global reach, and service portfolio diversity: (...) Hovione – Offers particle engineering and inhalation development, with a focus on dry powder inhalers. (...) These companies are continually investing in facilities, talent, and technology to meet evolving customer needs in the inhalation CDMO market.   Read the full article on Pharmiweb.com        

Press Clipping

Inhalation CDMO Market Growth Analysis & Forecast 2025 to 2035

Jun 25, 2025